Using Raman Spectroscopy to Diagnose Extrahepatic Cholangiocarcinoma
Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma
NA · University Hospital Olomouc · NCT06964425
This study is testing a new way to diagnose extrahepatic cholangiocarcinoma using a special light technique during a procedure to see if it can better identify cancer in the bile ducts.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital Olomouc (other) |
| Locations | 1 site (Olomouc, Olomouc Region) |
| Trial ID | NCT06964425 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to enhance the diagnosis of extrahepatic cholangiocarcinoma by utilizing Raman spectroscopy, an optical method that analyzes scattered light to create a molecular 'fingerprint' of tissues. During endoscopic retrograde cholangiopancreatography (ERCP), a fiber Raman probe is introduced into the bile ducts to collect data from both cancerous and healthy tissues. The study involves performing multiple Raman spectroscopy measurements to develop a reliable methodology for in vivo diagnostics. The data collected will be analyzed by a specialized biophysicist to improve diagnostic capabilities.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who have a confirmed diagnosis of extrahepatic cholangiocarcinoma and require ERCP.
Not a fit: Patients who disagree with participation in the study will not benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could significantly improve the accuracy of diagnosing extrahepatic cholangiocarcinoma, leading to better patient outcomes.
How similar studies have performed: While this approach is novel, similar studies using Raman spectroscopy for other diagnostic purposes have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * person older than 18 years, who has known extrahepatic cholangiocarcinoma and is indicated for ERCP Exclusion Criteria: * disagreement with the study
Where this trial is running
Olomouc, Olomouc Region
- Peter Slodička — Olomouc, Olomouc Region, Czechia (RECRUITING)
Study contacts
- Principal investigator: Peter Slodička, M.D. — University Hospital Olomouc
- Study coordinator: Peter Slodička, M.D.
- Email: peter.slodicka@fnol.cz
- Phone: +420776807612
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma, Perihilar, Diagnosis, Raman Spectroscopy, Klatskin Tumor, Endoscopy, Biliary Stricture